A new study published in the European Journal of Nuclear Medicine and Molecular Imaging suggests that a hybrid imaging technique may finally bring quantitative rigor to this assessment. Researchers at Peking Union Medical College Hospital in Beijing prospectively enrolled 33 patients with thyroid-associated ophthalmopathy and scanned them on an integrated PET/MRI system using a radiotracer called 18F-NOTA-FAPI-04. Unlike conventional FDG, which tracks glucose metabolism in any active cell, FAPI tracers bind to fibroblast activation protein, a molecule displayed by activated fibroblasts and their inflammatory partners. Because thyroid eye disease is fundamentally a fibroinflammatory disorder of the orbital tissues, the tracer offers a way to visualize the cellular machinery driving the disease rather than its downstream anatomical consequences.

The technical logic of the study is worth unpacking. Each patient’s orbits were imaged simultaneously with PET, which quantifies molecular uptake, and with a battery of advanced MRI sequences that probe tissue microstructure. The MRI panel included T2 mapping, which reflects tissue water content and therefore edema; intravoxel incoherent motion diffusion imaging, which separates true water diffusion from blood flow within capillaries; and diffusion kurtosis imaging, which captures deviations from simple Gaussian diffusion and thus hints at tissue complexity. From these sequences the team extracted parametric maps of normalized T2 signal, the heterogeneity index alpha, the distributed diffusion coefficient, the diffusion coefficient, relative blood flow, mean diffusivity, and mean kurtosis. The goal was to see whether the molecular signal from PET and the microstructural signal from MRI tell the same story, and whether combining them outperforms either alone.

Participants were classified using the Clinical Activity Score, with eyes scoring three or higher considered active and those below three considered inactive. At the patient level, a person was labeled inactive only if both eyes were inactive. The researchers then extracted a rich set of quantitative features from each eye: PET metrics including maximum and mean standardized uptake values, metabolic tumor volume, and total lesion FAPI uptake, plus first-order histogram statistics such as mean, skewness, and kurtosis from each MRI parametric map. A support vector machine, a standard machine-learning classifier, was trained to distinguish active from inactive disease, and performance was evaluated with receiver operating characteristic analysis.

Reliability came first, and the numbers were reassuring. Interobserver and intraobserver agreement in delineating the orbital regions of interest was strong, with Dice similarity coefficients of 0.850, 0.880, and 0.901 for the different comparisons. Every quantitative PET and MRI parameter showed excellent reproducibility, with intraclass correlation coefficients above 0.907. In a field where subjective eyeballing of scans has long been the norm, this level of measurement stability matters: it means the features being fed into the classifier are not artifacts of who happened to draw the contours.

The correlation analysis produced one of the study’s most interesting nuances. At the patient level, where both eyes are averaged together, PET and MRI features correlated only weakly. But when each eye was analyzed as its own unit, the correlations strengthened considerably, particularly between PET uptake metrics and features derived from T2 mapping, the heterogeneity index, the diffusion coefficient, and mean diffusivity. This asymmetry makes biological sense. Thyroid eye disease is notoriously asymmetric, with one eye often far more inflamed than the other, and averaging across eyes dilutes the very signals that matter. The finding is a quiet argument for eye-level, rather than patient-level, imaging assessment in orbital disease.

The group comparisons confirmed that several quantitative features separate active from inactive disease. At the eye level, mean standardized uptake value, metabolic tumor volume, and total lesion FAPI uptake were all significantly higher in active eyes, while maximum standardized uptake value alone showed no significant difference, a reminder that peak values are often less informative than volume-weighted averages. On the MRI side, features from T2 mapping, the heterogeneity index, the diffusion coefficient, mean diffusivity, and mean kurtosis also differed significantly between active and inactive groups, consistent with the idea that active disease carries more edema and altered diffusion characteristics than fibrotic, quiescent tissue.

When it came to discriminating activity, the combined approach won. Among single PET parameters, mean standardized uptake value performed best at the patient level with an area under the curve of 0.759, while metabolic tumor volume led at the eye level with an AUC of 0.767. These are respectable but unremarkable figures, in the range of many clinical biomarkers. The combined PET/MRI model, however, pushed performance to an AUC of 0.844 at the patient level and 0.859 at the eye level. The improvement over either modality alone indicates that FAPI uptake and MRI-derived microstructural features carry complementary, not redundant, information about the state of the orbital tissues. In practical terms, the PET signal appears to capture the cellular fibroinflammatory process while the MRI parameters capture its tissue-level consequences, and the classifier benefits from having both.

The clinical implications are significant. Treatment for active thyroid eye disease, including high-dose glucocorticoids and newer targeted agents such as anti-IGF-1 receptor antibodies, works best early in the inflammatory phase and offers little once fibrosis has set in. Conversely, rehabilitative surgeries are best deferred until the disease is inactive. A quantitative imaging biomarker that reliably separates these phases could spare patients from ineffective treatment, reduce exposure to steroid side effects, and help time interventions more precisely. It could also serve as an objective endpoint in clinical trials, where the Clinical Activity Score’s known inter-observer variability has long complicated the interpretation of results. Prior studies have explored FDG-PET and multiparametric MRI separately for this purpose, but the FAPI tracer’s specificity for activated fibroblasts, combined with simultaneous MRI acquisition on a single scanner, represents a meaningful step forward in what the field calls molecular-radiological phenotyping.

Cautions remain, and the authors are candid about them. Thirty-three patients is a small cohort, and the classifier’s performance will need validation in larger, independent, and ideally multi-center populations before it can influence routine care. The Clinical Activity Score itself, used here as the reference standard, is an imperfect ground truth, which means the imaging model is being trained to reproduce a clinical judgment rather than to measure disease biology directly. The study was registered as a clinical trial and conducted under ethics approval at Peking Union Medical College Hospital, and the team notes that further validation is required. Still, the trajectory is clear: a single integrated scan that fuses molecular information about fibroblast activity with quantitative maps of tissue edema, perfusion, and diffusion could transform thyroid eye disease from a condition assessed by counting symptoms into one measured, monitored, and treated on the basis of what is actually happening inside the orbit. For a disease that can quietly steal sight, that kind of clarity cannot come soon enough.

Subject of Research: Quantitative assessment of disease activity in thyroid-associated ophthalmopathy using integrated 18F-NOTA-FAPI-04 PET/MRI

Article Title: Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy

Article References: Yang, X., Gan, L., Shi, X., Wu, M., Li, E., Zhang, Y., Hao, Z., Huang, Z., Xing, H., Liu, X., & Huo, L. (2026). Integrated 18F-NOTA-FAPI-04 PET/MRI for quantitative assessment of disease activity in thyroid-associated ophthalmopathy. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08157-x

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08157-x

Keywords: thyroid-associated ophthalmopathy, thyroid eye disease, PET/MRI, 18F-NOTA-FAPI-04, fibroblast activation protein, Clinical Activity Score, multiparametric MRI, intravoxel incoherent motion, diffusion kurtosis imaging, radiomics, support vector machine, Graves orbitopathy

The research, conducted by radiologist Yongjun Ni and neonatologist Shuhui Chen at Jiaxing Maternity and Child Health Care Hospital in Zhejiang Province, China, focused on a technique called intravoxel incoherent motion imaging, or IVIM. Unlike conventional diffusion-weighted MRI, which treats all movement of water molecules in tissue as a single phenomenon, IVIM separates two distinct processes. The first is true molecular diffusion, the random Brownian motion of water within cells and tissue spaces, quantified by a parameter known as D. The second is pseudo-diffusion, the incoherent motion of water driven by blood flowing through the microscopic network of capillaries, captured by the perfusion fraction f and the pseudo-diffusion coefficient D*. By fitting MRI signals acquired at multiple diffusion weightings, IVIM can effectively probe both the tissue architecture and the microcirculation of the placenta in a single examination.

This distinction matters because invasive placentas are not simply thicker or darker on a scan; they are biologically different. Abnormal vascular remodeling, disrupted tissue boundaries, and altered cellularity change both how water diffuses and how blood perfuses the placental tissue. The researchers reasoned that these microscopic changes should leave measurable fingerprints in the IVIM parameters, fingerprints that conventional MRI visual assessment alone might miss.

To test that idea, the team retrospectively analyzed 110 patients with placenta accreta spectrum who had undergone MRI at their institution. The cohort was divided into 47 women with invasive PAS, where the placenta penetrated deeply into or through the uterine wall, and 63 women with non-invasive disease. For each patient, the investigators compiled clinical data, reviewed conventional MRI findings such as morphological features and signal characteristics, and extracted the three IVIM parameters from regions of interest placed within the placenta. Measurement reliability was assessed using intraclass correlation coefficients, and the team checked that predictor variables were not redundantly entangled by examining variance inflation factors before modeling.

The statistical core of the study was multivariate logistic regression, a method that weighs multiple candidate predictors simultaneously to determine which ones independently distinguish invasive from non-invasive disease. Out of this process emerged six independent predictors, a combination of conventional MRI features and IVIM-derived parameters that together formed a prediction model. The model’s discrimination, its ability to separate invasive from non-invasive cases, was quantified with the area under the receiver operating characteristic curve, a standard metric in diagnostic research. On the original dataset, the model achieved an AUC of 0.926, with a 95 percent confidence interval of 0.889 to 0.953, a figure that places it in the range of excellent diagnostic performance.

Impressive as that number is, diagnostic models built and tested on the same data almost always look better than they truly are, a statistical phenomenon known as optimism. To address this, the researchers performed internal validation using bootstrap resampling, a technique that repeatedly draws random samples with replacement from the original dataset, refits the model on each resample, and measures how much its apparent performance overstates its true accuracy. After 1,000 bootstrap iterations, the optimism-corrected AUC settled at 0.887, with a confidence interval of 0.841 to 0.933. That the model retained strong discrimination after this correction is a meaningful signal of robustness, though the authors are explicit that external validation in independent cohorts is required before the model can be implemented clinically.

The study went beyond diagnosis. Using ROC analysis, the researchers evaluated whether the IVIM parameters could also predict adverse clinical outcomes, the cascade of complications, including severe hemorrhage, disseminated intravascular coagulation, intensive care admission, and neonatal harm, that follows in the wake of invasive placentation. The combined IVIM parameters achieved an AUC of 0.866 for predicting these adverse outcomes, indicating that the microstructural and microvascular information captured by IVIM carries prognostic weight, not merely diagnostic value. In other words, the same numbers that help identify an invasive placenta may also foreshadow how stormy the clinical course will be.

The outcome analysis also delivered a sobering finding about newborns. Invasive PAS was significantly associated with adverse neonatal outcomes, with a relative risk of 5.203 and a 95 percent confidence interval of 1.646 to 16.446, meaning that babies born to mothers with invasive disease faced roughly five times the risk of complications compared with the non-invasive group. This statistic underscores why preoperative identification of invasive PAS is so consequential: knowing in advance allows delivery to be planned in a center with the surgical, blood banking, and neonatal intensive care capacity that these cases demand.

One association the data could not confirm involved fetal congenital anomalies. Although the point estimate suggested an elevated risk, with a relative risk of 6.787, the 95 percent confidence interval of 0.939 to 49.039 crossed unity, and none of the individual malformation categories reached statistical significance. Critically, these estimates rested on only eight events in total, a sample so small that the analysis was severely underpowered. The authors are careful to state that no established association between invasive PAS and congenital anomalies can be inferred from this dataset, a caveat that guards against overinterpretation of an intriguing but unproven signal.

The work was approved by the Ethics Committee of Jiaxing Maternity and Child Health Care Hospital, conducted in accordance with the Declaration of Helsinki, and supported by the Jiaxing Public Welfare Research Program. Its practical promise lies in a workflow that obstetric units could realistically adopt: when ultrasound or clinical risk factors raise suspicion of PAS, an IVIM-enabled MRI protocol could quantify diffusion and perfusion parameters alongside conventional imaging signs, feeding a validated statistical model that flags invasive disease and predicts the likelihood of a complicated course. With cesarean rates rising globally and PAS incidence climbing in parallel, a noninvasive tool that turns uncertainty into quantified risk could spare mothers from unprepared emergencies and give surgical teams the one resource they value most before a dangerous delivery: time to plan.

Subject of Research: Using intravoxel incoherent motion MRI parameters combined with conventional imaging to predict invasive placenta accreta spectrum and adverse clinical outcomes

Article Title: Predicting invasive placenta accreta spectrum and adverse clinical outcomes using magnetic resonance imaging combined with intravoxel incoherent motion parameters

Article References: Ni, Y., & Chen, S. (2026). Predicting invasive placenta accreta spectrum and adverse clinical outcomes using magnetic resonance imaging combined with intravoxel incoherent motion parameters. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02735-z

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02735-z

Keywords: placenta accreta spectrum, magnetic resonance imaging, intravoxel incoherent motion, diffusion imaging, obstetrics, predictive model, logistic regression, neonatal outcomes, radiology, bootstrap validation, adverse clinical outcomes, Predicting